More recently, we found that genetic deletion or pharmacological inhibition of the PGE2 receptor EP1 reduces cerebral infarction, BBB damage and hemorrhagic transformation in an experimental ischemic stroke model, and these neuroprotective effects are associated with decreased MMP-9 levels and activity (29). Here, MMP9 is linked to cerebral infarction.